生物试剂
>
生化试剂
>
信号通路
> 溴芬酸钠
加入收藏 取消收藏

溴芬酸钠  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：250mg 1g 5g in glass bottle
溶解性：溶于DMSO（≥100mg/mL）和H2O（≥100mg/mL）
产品描述：基本信息 产品编号： B11247 产品名称： Bromfenac sodium hydrate CAS: 120638-55-3   储存条件 粉末 -20℃ 四年     分子式： C30H28Br2N2Na2O9 溶于液体 -80℃ 两年 分子量 383.17 -20℃ 一个月 化学名：  sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate Solubility (25°C)：   体外:   DMSO 100mg/mL(130.49mM) Ethanol Insoluble Water 100mg/mL(130.49mM) 体内(现配现用): 1.请依序添加每种溶剂：PBS Solubility:33.33mg/mL(86.98mM);Clear solution; Need ultrasonic 2.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline，Solubility:≥2.5mg/mL(6.52mM);Clear solution 此⽅案可获得≥2.5mg/mL(6.52mM，饱和度未知)的澄清溶液。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到400μLPEG300中，混合均匀；向上述体系中加⼊50μLTween-80，混合均匀；然后继续加⼊450μL⽣理盐⽔定容⾄1mL。 3.请依序添加每种溶剂：10% DMSO→90% (20% SBE-β-CD in saline) Solubility:≥2.5mg/mL(6.52mM);Clear solution 此⽅案可获得≥2.5mg/mL(6.52mM，饱和度未知)的澄清溶液。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到900μL20%的SBE-β-CD⽣理盐⽔⽔溶液中，混合均匀。 ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 1.3049mL 6.5245mL 13.0490mL 5mM 0.2610mL 1.3049mL 2.6098mL 10mM 0.1305mL 0.6525mL 1.3049mL 50mM 0.0261mL 0.1305mL 0.2610mL   生物活性 产品描述 一种有效的和具有口服活性的 COX 抑制剂。 靶点 COX () 体外研究 Bromfenac (90μg/mL; 48 h) inhibits TGF-b1-induced extracellular matrix (ECM) synthesis and myofibroblast activation in HConFs and HPFs Bromfenac (30-90μg/mL; 48 h) decreases the protein and mRNA expression levels of FN, COL3, a-SMA, and survivin in a dosedependent manner in HConFs and HPFs Bromfenac (30-90μg/mL; 48 h) declines the phosphorylated protein levels of AKT, ERK1/2, and GSK-3b-S9 with dosage in HPFs and HConFs 体内研究 Bromfenac (0.0032-3.16%; 100 or 200μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18h pretreatment time) in rats Bromfenac (0.032-3.16%; 100μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats Bromfenac (0.032-1.0%; 50μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs Bromfenac (0.0032-0.1%; 50μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats Bromfenac (0.32%; 50μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice Animal Model: Male Sprague-Dawley rats (150-250 g) are injected carrageenan Dosage: 0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.16% (100 or 200μL) Administration: Rubbed onto the backs before 1-72 h of injected carrageenan Result: Produced significant anti-inflammatory activity when applied 1, 2, and 4 h prior to carrageenan challenge at 0.32%.Applied 1 or 4 h prior to carrageenan challenge was active, but not when applied 24 h (or longer) prior to challenge at 0.2%.
保存条件：-20℃

猜你喜欢